eladocagene exuparvovec tneq - Generic Medications
Browse 1 brand name versions of eladocagene exuparvovec tneq. Review brand names, dosage forms, strengths, and linked product records.
KEBILIDI (eladocagene exuparvovec-tneq) is a gene therapy product that expresses the human aromatic L-amino acid decarboxylase enzyme (hAADC). It is a recombinant adeno-associated virus serotype 2 (rAAV2) based vector containing the complementary DNA of the human DDC gene under the control of the cytomegalovirus immediate-early promoter. Eladocagene exuparvovec-tneq is produced in human embryonic kidney cells by recombinant DNA technology. KEBILIDI is a sterile suspension administered by bilateral intraputaminal infusion in one surgical session at two sites (anterior and posterior) per putamen. Each single-dose 2 mL vial contains 2.8×10 11 vg in an extractable volume of 0.5 mL of suspension. Each mL of suspension contains 5.6×10 11 vg. Patients will receive a total dose of 1.8×10 11 vg delivered as four 0.08 mL (0.45×10 11 vg) infusions (two per putamen). KEBILIDI is provided in a single-dose 2 mL vial containing a clear to slightly opaque, colorless to faint white liquid, free of visible particulates following thaw from its frozen state. The excipients include potassium chloride (3 mM), sodium chloride (337 mM), potassium dihydrogen phosphate (2 mM), disodium hydrogen phosphate (8 mM), and poloxamer 188 (0.001%).
About eladocagene exuparvovec tneq Generic Drugs
This collection groups medications in our database under the generic name eladocagene exuparvovec tneq. It currently includes 1 matching listing.
What You Can Review
Use this page to compare the set of products we have indexed for this generic name. Each result links to more detailed product information and related landing pages.
Safety Information
Always consult a qualified healthcare professional before starting, stopping, or switching any medication. The information on this page is educational and should not replace medical advice.